electroCore closed the second quarter of 2026 with a 28% top-line gain to $9.5 million of net sales, a sequential softening from the $9.6 million reported in the first quarter, and a fresh explicit going-concern qualification from its auditor that resets the equity narrative around a single question: can the company fund the next twelve months of operations without an emergency capital event that materially dilutes the existing 9.0 million-share base. The underlying commercial franchise looks more credible than at any point in the company's history, with first-half revenue up 35% to $19.0 million, a gross margin that has held at 86.5% in the quarter and 86.9% year to date, and a Federal Supply Schedule contract with the U.S. Department of Veterans Affairs that now expires in 2030 and which accounted for 75.8% of second-quarter net sales. The 24% year-on-year expansion in prescription revenue, the May 2025 acquisition of NURO and its Quell Fibromyalgia product, and the continuing commercialization of the Truvaga Plus wellness handset are the three commercial engines that have changed the shape of the business.
The three variables that determine the equity outcome are, in order, the cash runway and the timing of a capital raise, the durability of the VA channel as the single-customer concentration widens, and the speed at which the Truvaga and TAC-STIM non-prescription businesses can grow enough to dilute the VA dependency before the Avenue Venture debt principal amortization of $2.5 million in 2027 and $3.0 million in 2028 begins to compress the balance sheet. Each of these variables has an explicit tracking signal: the cash position moved from $11.6 million at year-end 2025 to $10.0 million at June 30, 2026, and the company disclosed in the second-quarter 10-Q that its currently forecasted cash is less than the requirements to fund its operating expenses and capital expenditure requirements for at least the next twelve months. The VA channel printed 75.8% of revenue in the quarter versus 71.8% in the prior-year quarter, and Truvaga grew 29% to $1.3 million in the quarter while TAC-STIM was effectively flat at $185 thousand.
The thesis confirms if electroCore can print third-quarter revenue at a pace consistent with the second quarter while executing either a registered offering or a strategic capital event before the cash position erodes below what the FSS contract renewal cycle would tolerate. The thesis breaks if a second consecutive quarter of single-digit sequential top-line growth, an adverse outcome in the Pulsetto patent litigation that begins active mediation on September 10, 2026, or an additional FDA Form 483 follow-up inspection forces electroCore to access the Avenue debt on punitive terms or to clear the at-the-market facility at a price below the $8.17 weighted-average realized during the second quarter. The market is mispricing the going-concern flag as a fatal signal when it is in fact a timing signal. The company is the smallest pure-play nVNS franchise in U.S. listed medtech, but its revenue mix, its FSS contract through 2030, and its $100 million shelf registration position give the equity optionality that the current sub-$10 share price does not reflect.